{"slideshow_credits": null, "snippet": "William A. Ackman and Valeant Pharmaceuticals lost their hostile battle to buy Allergan and still came away with a total of $2.6 billion.", "abstract": "William A. Ackman and Valeant Pharmaceuticals lost their hostile battle to buy Allergan and still came away with a total of $2.6 billion.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"lastname": "SORKIN", "rank": 1, "firstname": "Andrew", "role": "reported", "organization": "", "middlename": "Ross"}], "original": "By ANDREW ROSS SORKIN"}, "web_url": "http://dealbook.nytimes.com/2014/11/17/the-luck-of-a-loser-to-the-tune-of-2-2-billion/", "lead_paragraph": null, "headline": {"main": "Ackman Has Luck of a Loser, to the Tune of $2.2 Billion", "print_headline": "The Luck of a Loser, to the Tune of $2.2 Billion", "kicker": "DealBook"}, "_id": "546aa76e38f0d84ca2c5c90c", "word_count": "889", "multimedia": [{"height": 126, "url": "images/2014/11/18/business/Sorkin/Sorkin-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/11/18/business/Sorkin/Sorkin-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 399, "url": "images/2014/11/18/business/Sorkin/Sorkin-articleLarge.jpg", "legacy": {"xlarge": "images/2014/11/18/business/Sorkin/Sorkin-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "399"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/11/18/business/Sorkin/Sorkin-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/11/18/business/Sorkin/Sorkin-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-11-17T20:55:55Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Ackman, William A", "name": "persons", "is_major": "Y", "rank": "1"}, {"value": "Allergan Inc", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Actavis PLC", "name": "organizations", "is_major": "N", "rank": "3"}, {"value": "Pershing Square Capital Management", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "is_major": "Y", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1"}, {"value": "Hedge Funds", "name": "subject", "rank": "2"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "3"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}